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Abstract
Human enterovirus 71 (EV-71) is the main etiologic agent of hand, foot and mouth disease 
(HFMD). We sought to identify EV-71 specific antigens and develop serologic assays for acute-
phase EV-71 infection. A series of truncated proteins within the N-terminal 100 amino acids (aa) 
of EV-71 VP1 was expressed in Escherichia coli. Western blot (WB) analysis showed that 
positions around 11–21 aa contain EV-71-specific antigenic sites, whereas positions 1–5 and 51–
100 contain epitopes shared with human coxsackievirus A16 (CV-A16) and human echovirus 6 
(E-6). The N-terminal truncated protein of VP1, VP16–43, exhibited good stability and was 
recognized by anti-EV-71 specific rabbit sera. Alignment analysis showed that VP16–43 is highly 
conserved among EV-71 strains from different genotypes but was heterologous among other 
enteroviruses. When the GST-VP16–43 fusion protein was incorporated as antibody-capture agent 
in a WB assay and an ELISA for detecting anti-EV-71 IgM in human sera, sensitivities of 91.7% 
and 77.8% were achieved, respectively, with 100% specificity for both. The characterized EV-71 
VP1 protein truncated to positions 6–43 aa has potential as an antigen for detection of anti-EV-71 
IgM for early diagnosis of EV-71 infection in a WB format.
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1. Introduction
Human enterovirus 71 (EV-71) and human coxsackievirus A16 (CV-A16), belonging to 
human enterovirus species A of the genus Enterovirus within the family Picornaviridae, are 
the two major causative agents of hand, foot and mouth disease (HFMD). HFMD is a 
common febrile disease, which mainly affects infants and young children, resulting in the 
appearance of vesicular rashes on hands, feet, and buccal mucosa (Hagiwara et al., 1978). In 
severe cases, EV-71 infection may lead to neurological complications, such as aseptic 
meningitis, brainstem encephalitis and acute flaccid paralysis with high incidence of fatality 
(Lee et al., 2009). EV-71, first identified in California in 1969 (Schmidt et al., 1974), has 
spread to cause widespread epidemics around the world, especially in Southeast Asia 
(AbuBakar et al., 1999; Ahmad, 2000; Chan et al., 2000; Chang, 2008; Liu et al., 2000). In 
China, EV-71 infection has resulted in at least 1600 deaths from 2008 to 2012 (Xing et al., 
2014). EV-71 is now regarded as the most important neurotropic enterovirus in the Asia-
Pacific region in the post-polio eradication era (Bible et al., 2007; Wong et al., 2010). As 
there are no effective antiviral agents or vaccines available for treatment and prevention of 
EV-71 infection, early and rapid diagnosis of EV-71 infection is critical to implementing 
timely clinical management and public health intervention.
The standard laboratory diagnosis of EV-71 infection is based on a conventional virus 
isolation and identification by neutralization test or immunofluorescence assay, which is 
labor intensive, subjective, and time-consuming. Molecular diagnostic assays for EV-71 
based on conventional or real-time RT-PCR have been developed and widely used in 
clinical practice, which require dedicated, expensive equipment and maintenance of separate 
areas to avoid contamination. So, these methods are unsuitable as point of care assays in 
most community clinics in developing countries. Serological diagnosis using enzyme 
immunoassay (EIA) is an alternative approach owing to its usage of basic laboratory 
equipment. In recent years, a few IgM-capture ELISA assays have been developed for early 
and rapid diagnosis of EV-71 infection (Tano et al., 2002; Tsao et al., 2002; Wang et al., 
2004; Xu et al., 2010). These approaches use, as antibody-capture agent, purified whole 
EV-71 virion, which can bind to antibodies that cross-react with other enteroviruses.
VP1 is a major and immunodominant capsid protein of EV-71. Recombinant VP1 protein 
has been investigated as an antigen for serological diagnosis (Shih et al., 2000). In a 
previous study we have found that full-length VP1 possesses strong cross-reactivity with 
sera raised against CV-A16 and human echovirus 6 (E-6) (Zhang et al., 2012). We also 
found that the major immunoreactive region of the VP1 protein is located at the N-terminus, 
between amino acid (aa) positions 1–100. We report here that recombinant truncated protein 
VP1 located between positions 6–43 aa is a potential antigen for use in the early serologic 
diagnosis of EV-71 infection.
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2. Materials and methods
2.1. Cells and viruses
Human rhabdomyosarcoma (RD) cells were grown in Dulbecco’s modified Eagle’s medium 
(Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum plus 100 IU of 
penicillin and 100 μg/ml of streptomycin. Three local enterovirus strains, designated EV-71/
MAS01/AH/CHN/09 (GenBank accession No. JQ409495), CV-A16/MAS01/AH/CHN/10 
(GenBank accession No. JQ409499) and E-6/NJ01/JS/CHN/10 (GenBank accession No. 
JQ409486), were isolated and cultured in RD cells.
2.2. Serum specimens
As described previously, three antisera against EV-71, CV-A16 and E-6 were prepared by 
immunizing New Zealand white rabbits with the three heat-inactivated viruses respectively 
(Zhang et al., 2012). Serum samples were obtained from 51 children diagnosed with HFMD 
upon admission to the Nanjing Children’s Hospital. Virus-specific diagnosis was established 
by the detection of RNA from EV-71, CV-A16 or other enteroviruses in throat or anal swabs 
following reverse-transcriptase-PCR with primers specific for EV-71, CV-A16 and pan-
enterovirus (PEV) (Liu et al., 2011). Negative control sera were collected from 87 healthy 
children (<5 years old) in kindergartens in Shaoxing city, who were confirmed to be 
uninfected with EV-71, having tested negative serologically for antibodies against EV-71 
using an in vitro neutralization assay as described previously (Zhang et al., 2012).
2.3. Construction of the recombinant plasmids
The VP1 gene derived from strain EV-71/MAS01/AH/CHN/09 was used as template to 
amplify the coding regions of the N-terminal VP1 using the Expand High Fidelity PCR 
system (Roche Diagnostics GmbH, Mannheim, Germany). All forward primers were 
designed with the EcoR I restriction site, and the reverse primers were designed with the Not 
I restriction site and a stop codon at the 5′ end (Table 1). The cloned fragments were 
digested with EcoR I and Not I (NEB, Ipswich, MA, USA), purified and inserted into the 
prokaryotic expression vector pGEX-5X-1 (GE Healthcare, Piscataway, NJ, USA) to 
generate recombinant plasmids. Successful ligation was verified by sequencing.
2.4. Expression and purification of the recombinant proteins
Escherichia coli BL21 (DE3) transformed with the recombinant plasmids was cultured in 
Luria broth (LB) medium supplemented with ampicillin (50 μg/ml) at 37 °C. When the 
cultures reached an optical density of 0.6–0.8 at 600 nm, the cells were induced with 
isopropyl-β-D-thiogalactopyranoside (IPTG; 1 mM) and growth was continued for 3–5 h. 
The cells were harvested by centrifuging at 8000 × g for 10 min at 4 °C. The pellets were 
suspended in Tris–HCl buffer (50 mM; pH 7.9) supplemented with Triton X-100 (0.1%; 
v/v), lysozyme (1 mg/ml) and MgCl2 (4 mM). Subsequently, the lysates were treated with 
DNase (5 mg/ml) and RNase (5 mg/ml) for 30 min at 25 °C. After centrifugation at 20,000 × 
g for 15 min at 4 °C, the clear supernatant was collected and used for solubility analysis and 
purification. All the GST fusion proteins were purified using glutathione sepharose 4B (GE 
Healthcare, Piscataway, NJ, USA) according to the GST gene fusion system handbook. The 
Zhang et al. Page 3
Virus Res. Author manuscript; available in PMC 2016 January 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
protein purity and concentration were measured using the SDS-PAGE and the Bradford 
assay.
2.5. Western blot (WB) analysis
Approximately 1 μg of the GST fusion protein was run in 15% SDS-PAGE under denaturing 
conditions, and transferred to nitrocellulose membrane. The blotted membrane was blocked 
with TBST containing 5% (m/v) non-fat milk. Serum samples were diluted 1:100 in 
blocking buffer, added to the membranes and incubated overnight at 4 °C. The membrane 
was rinsed and incubated for 1 h with affinity-purified goat anti-rabbit IgG, or goat anti-
human IgM conjugated to horseradish peroxidase (KPL, Gaithersburg, MD, USA) diluted 
1:2000 in blocking buffer. After washing, color development was carried out with 3,3′ -
diaminobenzidine. To test all human serum specimens simultaneously, WB analysis was 
performed using a 20-channel Mini-Protean II multiscreen apparatus (Bio-Rad, Hercules, 
CA, USA).
2.6. Indirect ELISA
Purified GST fusion proteins, diluted to a final working concentration (10 ng/μl) in PBS (pH 
7.4) were added to microwell immunoassay strips to a final volume of 100 μl per well. The 
strips were coated overnight at 4 °C and blocked with 1% BSA in PBS. After washing, 100 
μl of the serum samples at a dilution of 1:100 were added to each well, and the strips were 
incubated for 45 min at 37 °C. After washing again, HRP-conjugated goat antihuman IgM 
(KPL, Gaithersburg, MD, USA) was added at a dilution of 1:5000. Finally, the reaction was 
developed using 100 μl/well of tetramethylbenzidine (TMB) (Sigma–Aldrich, St Louis, MO, 
USA) substrate, and optical density values were determined.
2.7. Computational and sequence analyses
The amino acid sequence of the truncated VP1 protein fragment was used as query sequence 
for BLAST analysis (blastp 2.2.26+) against all enterovirus entries in the National Center of 
Biotechnology Information (NCBI) database. Amino acid sequence alignment was 
performed using the ClustalW algorithm of DNAStar MegAlign.
3. Results
3.1. Expression and purification of truncated VP1 proteins
Nine overlapping PCR fragments encoding different N terminal segments of VP1 within 
positions 1–100 aa were amplified separately and inserted into pGEX-5X-1 (Fig. 1a). 
Expression of cloned transformants was induced with protein was in agreement with the 
expected molecular weight (Table 2). All fusion proteins were soluble, and purified using 
glutathione sepharose 4B under native conditions. The purity of all the purified proteins was 
high by analysis with SDS-PAGE (Fig. 1b). The fusion proteins VP11–100, VP16–100, 
VP111–100 and VP121–100 were unstable (Fig. 1b, lanes 1–4). The smaller proteins VP1–50 
and VP6–50 were also unstable (Fig. 1b, lanes 5 and 8). However, after removing seven or 
more amino acid residues from the carboxyl terminus of VP1–50 or VP6–50, fusion proteins 
VP11–40, VP11–30 and VP16–43 were stable (Fig. 1b, lanes 6, 7 and 9). These observations 
suggested that positions 44–50 aa confer instability in these proteins.
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3.2. Mapping of EV-71 specific antigenic fragment by WB analysis
Immunoreactivity of the nine truncated VP1 proteins was tested using WB assay with rabbit 
antisera against EV-71, CV-A16 and E-6, respectively. VP11–100 and its C-terminal 
truncated proteins, VP11–50, VP11–40 and VP11–30, reacted strongly with anti-EV-71 sera. 
Two N-terminal truncated proteins (VP16–100 and VP111–100) also showed strong reactivity 
to anti-EV-71. However, after truncation of 10 amino acids from VP111–100 the reaction of 
VP121–100 to anti-EV-71 became weaker. These results suggested that the VP1 region 
around positions 11–21 aa contains a major immunoreactive site to anti-EV-71 (Table 2). As 
demonstrated previously (Zhang et al., 2012) and again in this study, VP11–100 exhibited 
cross-reactivity with rabbit antisera against CV-A16 and E-6. Three C-terminal truncated 
proteins, VP11–50, VP11–40 and VP11–30, also reacted with anti-CV-A16 sera, but did not 
react with anti-E-6 sera. Three N-terminal truncated proteins, VP16–100, VP111–100 and 
VP121–100 reacted with both anti-E-6 and anti-CV-A16 sera. However, the cross-reactivity 
to anti-CV-A16 was reduced comparing to the reactivity of VP11–100. The remaining two 
proteins, VP16–50 and VP16–43, were reactive to anti-EV-71 sera only, and unreactive to 
anti-CV-A16 or anti-E-6 sera (Table 2). These results suggest that EV-71’s VP1 region 
between positions 51–100 aa contains epitopes shared with E-6 and CV-A16. There is an 
additional epitope shared with CV-A16 at the N-terminus, between positions 1–5 aa. Taking 
into account the instability of VP16–50, protein VP16–43 was chosen for further analysis as a 
candidate for EV-71-specific diagnostic reagent.
3.3. Alignment analysis of aa sequences of EV-71 VP16–43
Protein-protein BLAST analysis revealed that the amino acid sequence of EV-71 VP16–43 
contains high homology (89.5–100%) among heterologous EV-71 strains from different sub-
genotypes, and relatively low homology (26–55%) with other viruses from species A 
enteroviruses. No significant homology was found among enteroviruses from species B, C 
or D except for poliovirus (homology 23–29%) (Table 3). Alignment using the ClustalW 
algorithm of the program MegAlign (DNAStar) also showed that the sequence at positions 
6–43 aa of VP1 was highly conserved among all EV-71 strains from the different genotypes 
and sub-genotypes and different from the sequences of strains of CV-A16 and E-6 (Fig. 2).
3.4. Detection of anti-EV-71 IgM in human sera using the fusion protein GST-VP16–43
Human serum specimens were collected from 51 HFMD patients infected with EV-71 (n = 
36), CV-A16 (n = 8) and other enteroviruses or non-enteroviruses (n = 7). Negative control 
sera were collected from 87 healthy children. The WB assay using recombinant protein 
GST-VP16–43 showed that sera from 33 of the 36 EV-71-infected patients were positive 
(91.7%), and the remaining 15 sera from HFMD patients infected with non EV-71 were 
negative (Table 4). The utility of GST-VP16–43 was also investigated using indirect IgM 
ELISA. Checkerboard titration revealed that the most appropriate dilutions for the fusion 
protein and HRP-conjugated goat antihuman IgM were 1:200 (1 μg/ml) and 1:5000 
respectively. After the 87 negative control sera were tested, the cut-off OD value was 
calculated as the mean plus two standard deviations of the negative sample. Mean OD value 
was 0.074 and the standard deviation was 0.053; the cut-off value was set as 0.180. Of the 
36 sera collected from EV-71 infected patients, 28 sera (77.8%) were positive, and all 15 
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sera from patients with non EV-71 infections were negative (Table 4). These data shown 
that none of false positive results was observed in both ELISA and immuno-blot assay, but 
the sensitivity of anti-EV-71 IgM detection depends on the method used (WB or ELISA) 
although the same antigen GST-VP16–43 is applied.
4. Discussion
Early diagnosis is essential for effective clinical management and control of infectious 
diseases. Generally, IgM antibody will be detectable very early after primary infection for 
EV-71 infection. Therefore, detection of anti-EV-71 IgM based on enzyme immunoassay 
(EIA) should be an ideal method for early and rapid diagnosis of EV-71 infections. The key 
to developing this technique is to choose an appropriate antigen with high sensitivity and 
specificity.
Recent studies have reported the purification of whole EV-71 particles used as antigen to 
develop μ-capture ELISA for anti-EV-71 IgM detection (Tano et al., 2002; Tsao et al., 2002; 
Wang et al., 2004).Xu et al. (2010) assessed the performance of anti-EV-71 IgM detection 
using μ-capture ELISA, which showed an acceptable sensitivity in EV-71 infected patients, 
and a satisfactory specificity in non-HFMD children and healthy adults. However, out of 
332 sera from cases of non-EV-71 enterovirus infection, 38 sera (11.4%) showed anti-
EV-71 IgM positivity. This substantial false negative rate was assumed to be due to cross 
reactivity to common epitopes among enteroviruses. In addition, the preparation of whole 
EV-71 particles was cumbersome and time-consuming because of the use of cell culture 
followed by virus purification and inactivation, and the need to monitor the inactivation 
process.
The EV-71 capsid protein VP1 had also been considered for use as a diagnostic antigen. 
Recombinant EV-71 VP1 expressed in E. coli can react specifically with antibodies from 
patients infected with EV-71 by the WB assay (Shih et al., 2000). However, in our previous 
study EV-71 VP1 possessed strong cross-reactivity with antisera against CV-A16 and E-6, 
which suggested recombinant EV-71 VP1 is not a suitable antigen for specific serodiagnosis 
of EV-71 infection (Zhang et al., 2012). Further study showed that the major 
immunoreactive region of the VP1 protein was located in the N-terminal part at position 1–
100 aa. However, truncated His-VP11–100 protein still contains cross-reactive sites 
recognized by antibodies against CV-A16 and E-6 (Zhang et al., 2012).
In this study, GST-tag fusion protein VP11–100 and a series of truncated proteins were 
expressed in E. coli and investigated for their immunoreactivity. WB analyses showed that 
VP11–100 and its C-terminal truncated proteins (VP11–50, VP11–40 and VP11–30) reacted 
strongly with antibodies against EV-71. Two N-terminal truncated proteins (VP16–100, 
VP111–100) also showed strong reactivity. However, VP121–100, truncated 20 aa from N-
terminus, reacted weakly. Recently, two non-neutralizing linear epitopes were found at 
positions 3–8 and 12–19 aa of VP1 (Lim et al., 2013; Man-Li et al., 2012). The truncated 
proteins (VP16–100, VP111–100) do not contain a complete copy of the 3–8 epitope. 
Compared with VP11–100, however, the immunoreactivity of VP16–100 and VP111–100 was 
not significantly reduced. These results suggest that a VP1 N-terminal region at positions 
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around 11–21 aa contains the major EV-71 immunoreactive sites. Similar with our results, a 
linear epitope located at 6–20 aa of EV-71 VP1 was identified recently by a non-neutralizing 
monoclonal antibody (MAb 27) and highly conserved among all EV-71 subgenotypes (Xu et 
al., 2013).
The N-terminal VP1 region spanning from positions 51 to 100 aa contains CV-A16 and E-6 
cross-reactive sites, and the first 5 aa in the N-terminus contains an additional CV-A16-
cross-reactive site. Without these cross-reactive sites, the VP16–50 and VP16–43 should 
specifically recognize antibodies against EV-71. Due to the instability of the VP16–50, only 
the VP16–43 was chosen for further study for its potential application in early diagnosis of 
EV-71 infection.
Sequence analysis showed that the VP16–43 was highly conserved among all strains that 
represent genotypes A, B and C of EV-71, and exhibited relatively low homology with other 
enteroviruses in species A–D. As further proof of concept, WB analysis and an indirect 
ELISA based on the GST-VP16–43 were developed to detect anti-EV-71 IgM antibodies. 
The sensitivity of the WB assay and the ELISA was 91.7% (33/36) and 77.8% (28/36), 
respectively, and the specificity was 100% for the both tests. The relatively lower sensitivity 
of the indirect ELISA may be attributed to anti-EV-71-specific IgG in test sera, which 
competed with EV-71-specific IgM for antigen binding, thereby generating false-negative 
results. Foo et al. (2008) reported a very similar result, in which a GST fusion protein 
harboring an EV-71-specific antigenic epitope did not react with anti-EV-71 IgG antibodies 
in ELISA but was strongly reactive to the antibodies in WB assay. Therefore, the indirect 
ELISA format, perhaps, is not a suitable approach for anti-EV-71 antibody detection with 
some special antigens.
In summary, we reported here that a truncated protein segment located at N-terminus (6–43 
aa) of EV-71 VP1 contains an EV-71-specific antigenic site. It can be easily prepared with 
high solubility, purity and stability from recombinant E. coli. Although the present 
sensitivity is not enough to make a diagnostic kit with the antigen for anti-EV-71 IgM 
detection, its high specificity will encourage us to do further studies to improve the assays. 
This novel assay may be developed as immunoblot strip format. Moreover, changing the 
indirect format to IgM-capture format may also be an effective way to raise the sensitivity. 
Making multiple epitope or mosaic epitope antigen based on the findings in the present or 
other studies may also need to be considered. Efforts to explore more EV-71-specific 
epitopes and prepare recombinant antigens containing such epitopes are essential for 
establishing a simple and economic serodiagnostic assay for early diagnosis of EV-71 
infection.
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Fig. 1. 
Expression and purification of EV-71 VP1 truncated proteins located along the first 100 aa 
of the N-terminus. (a) Schematic representation of truncated proteins expressed in E. coli. 
(b) Purified recombinant proteins were separated on a 15% SDS-PAGE gel and stained with 
Coomassie blue. Lane M: protein molecular weight marker in kDa; lane 1, VP11-100; lane 
2–4: VP16–100, VP111–100, and VP121–100; lane 5–7: VP11–50, VP11–40, and VP11–30; lane 
8, VP16–50; lane 9, VP16–43; lane 10: GST.
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Fig. 2. 
Alignment of EV-71 VP1 sequences at positions 1–50 aa with heterologous EV-71 strains 
from different sub-genotypes, CV-A16 and E-6 strains. The VP1 region 6–43 aa is boxed. 
Asterisks (*) denote three local enterovirus strains.
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Table 1
Oligonucleotides primers for the construction of recombinant plasmids.
Primersa Sequence (5′ → 3′)b
VP1-F1 (EcoR I) CCGGAATTCGGAGATAGGGTGGCAGATGT
VP1-F6 (EcoR I) CCGGAATTCGATGTAATTGAAAGTTCCATAGG
VP1-F11 (EcoR I) CCGGAATTCTCTATAGGAGATAGCGTGAG
VP1-F21 (EcoR I) CCGGAATTCACTCACGCTCTACCAGCACC
VP1-R30 (Not I) TATGCGGCCGCCTACTGGCCTGTGGGTGCTGGT
VP1-R40 (Not I) TATGCGGCCGCCTAATCCAGTCGATGACTGCT
VP1-R43 (Not I) TATGCGGCCGCCTACTTGCCTGTATCCAGTCGATG
VP1-R50 (Not I) TATGCGGCCGCCTAAGCAGCTTGGAGTGCTGAAACC
VP1-R100 (Not I) TATGCGGCCGCCTATGTGCCCTCAAGAGGGAGAT
aAll primers are designed using the VP1 gene sequence of EV-71 MAS01/AH/CHN/09 (GenBank accession No. JQ409495). The number in the 
name of primer denotes the location of amino acid from N- or C-terminus of VP1, as F (forward) and R (reverse), respectively.
b
Letters in boldface and italics denote the recognition sequences of restriction enzymes.
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Table 3
Summary of blastp results using the EV-71 VP16–43 aa sequence as query against other enteroviruses.
Species Serotypes Identity (%)
A
Enterovirus 71 89.5–100
Coxsackievirus A16 44–55
Coxsackievirus A7 39–45
Enterovirus 89–91 38–44
Coxsackievirus A14 42
Coxsackievirus A5 39–42
Coxsackievirus A10 37–42
Coxsackievirus A8 41
Coxsackievirus A12 39
Coxsackievirus A3 37
Coxsackievirus A2 34–37
Coxsackievirus A4 31–37
Coxsackievirus A6 26–37
Enterovirus 76 26–33
B
Coxsackievirus A9 –
Coxsackievirus B1–6 –
Echovirus 1–7, 9,11–21, 24–27, 29–33 –
Enterovirus 69, 73–75, 77–78 –
C
Coxsackievirus A1, A11, A13, A15 –
Poliovirus 1–3 23–29
D Enterovirus 68, 70 –
“–” denotes no significant similarity found.
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